Trubion to cut staff in uncertain capital markets
This article was originally published in Scrip
Executive Summary
Trubion Pharmaceuticals has cut a quarter of its staff "in the face of continuing uncertainty in the capital markets and global economy". The autoimmune, inflammatory and cancer drug developer said that the 25 job eliminations will help the firm cut costs and realign its business toward its strongest near-term opportunities.